Roche stops olesoxime development
Roche stops the development of olesoxime, a neuroprotective drug that showed benefit in spinal muscular atrophy.
UK campaign for access to treatments and support for those with spinal muscular atrophy
BLOG ARCHIVE
Roche stops olesoxime development
Roche stops the development of olesoxime, a neuroprotective drug that showed benefit in spinal muscular atrophy.
Biogen responds to the open letter
Biogen responds to the open letter of UK SMA charities regarding SMC recommendation
Biogen responds to the open letter
Biogen responds to the open letter of UK SMA charities regarding SMC recommendation
Open letter to Biogen regarding SMC advice
Open letter to Biogen following SMC recommendation
Open letter to Biogen regarding SMC advice
Open letter to Biogen following SMC recommendation
Update on branaplam progress
Another potential treatment for SMA is progressing fast
Update on branaplam progress
Another potential treatment for SMA is progressing fast
Biogen’s statement on the SMC decision
Biogen’s statement re. Scottish decision on nusinersen availability